Drugs / MK-8892
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02078557 | May → Aug 2014 | left ventricular failure, pulmonary hypertension | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01934647 | Nov 2013 → Sep 2014 | pulmonary arterial hypertension | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 1 | NCT01926509 | Nov 2013 → Sep 2014 | pulmonary arterial hypertension | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01798849 | Mar → Jul 2013 | pulmonary arterial hypertension | Merck Sharp & Dohme LLC | Completed | Mixed |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-8892 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02078557 ↗ |
| Route | Oral | “MK-8892 given as single oral doses” NCT01798849 ↗ |